Orbimed Advisors LLC Cytom X Therapeutics, Inc. Transaction History
Orbimed Advisors LLC
- $2.93 Billion
- Q3 2025
A detailed history of Orbimed Advisors LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 8,461,500 shares of CTMX stock, worth $32.7 Million. This represents 0.92% of its overall portfolio holdings.
Number of Shares
8,461,500
Previous 8,461,500
-0.0%
Holding current value
$32.7 Million
Previous $19.2 Million
40.53%
% of portfolio
0.92%
Previous 0.69%
Shares
6 transactions
Others Institutions Holding CTMX
# of Institutions
109Shares Held
121MCall Options Held
1.49MPut Options Held
258K-
Vr Adviser, LLC New York, NY15.6MShares$60.1 Million7.54% of portfolio
-
Tang Capital Management LLC San Diego, CA11.1MShares$42.7 Million1.6% of portfolio
-
Perceptive Advisors LLC New York, NY9.68MShares$37.4 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.95MShares$34.5 Million0.0% of portfolio
-
Commodore Capital LP New York, NY7.69MShares$29.7 Million1.57% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $255M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...